TK-NOG Mouse Model

NOD Background

  • Model #
  • Genotype
  • Nomenclature
  • 12907-F
    NOD.Cg-Prkdcscid Il2rgtm1Sug Tg(Alb-TK)7-2/ShiJic
  • 12907-M
    NOD.Cg-Prkdcscid Il2rgtm1Sug Tg(Alb-TK)7-2/ShiJic
  • Super immunodeficient NOG mouse with transgenic expression of thymidine kinase under control of liver-restricted albumin promoter
  • Useful for humanizing liver via engraftment with human hepatocytes and/or humanizing immune system via engraftment of human immune cells/tissues or hematopoietic stem cells
  • Inducible ablation of murine hepatocytes by ganciclovir treatment enables stable, long-term engraftment of human hepatocytes.
  • The premiere model for human liver toxicity, metabolism, and infectious disease.
  • Other uses include safety and immunogenicity assessment
  • Liver/Immune humanized TK-NOG mice are under development. Please contact us to learn more about availability of these tissue humanized TK-NOG Mice.


The NOG mouse was developed by Mamoru Ito of the Central Institute for Experimental Animals (CIEA) in Japan. The Prkdc scid mutation was identified by Mel Bosma of the Fox Chase Cancer Center in a C.B-17 congenic mouse population. This mutation was backcrossed onto the NOD/ShiJic strain at CIEA for at least eight generations. The Il2rg targeted mutation was developed by Dr. Kazuo Sugamura of Tohoku University by targeting the gene in ES cells derived from a 129 strain. Targeted ES cells were injected into C57BL/6 blastocysts. Resultant chimeras were backcrossed onto the C57BL/6JJic background for at least eight generations. The NOG mouse was developed by backcrossing the C57BL/6JJic-Il2rg line to the NOD/ShiJic-Prkdc scid line for a total of eight generations. The HSVtk transgene was generated by CIEA via microinjection into NOD/Shi inbred mice. The transgenic construct contains the mouse albumin enhancer/promoter (mAlb En/Pro), the chimeric intron, HSVtk cDNA, and the 3'-UTR of the human growth hormone gene with a polyadenylation signal (hGH pA). There was a single site of transgene integration, and HSVtk mRNA was selectively expressed in the liver. The TK-NOD/Shi mice were backcrossed onto the NOG mouse at CIEA and imported into Taconic in 2014.





Initial Publication:

Hasegawa M, Kawai K, Mitsui T, Taniguchi K, Monnai M, Wakui M, Ito M, Suematsu M, Peltz G, Nakamura M, Suemizu H. The reconstituted 'humanized liver' in TK-NOG mice is mature and functional. (2011) Biochem Biophys Res Commun. 18;405(3):405-10.

Ito M, Hiramatsu H, Kobayashi K, Suzue K, Kawahata M, Hioki K, Ueyama Y, Koyanagi Y, Sugamura K, Tsuji K, Heike T, Nakahata T. (2002) NOD/SCID/γnull/c mouse: an excellent recipient mouse model for engraftment of human cells. Blood 100(9):3175-3182.

Nonprofit users (excluding users at nonprofit foundations which are affiliated with a for-profit entity): For internal research purposes, the TK-NOG Conditions of Use for nonprofit users apply. If you wish to perform sponsored research or fee-for-service contract research using this line, you must purchase under the for-profit terms and pricing.

For-profit users and users at foundations which are affiliated with for-profit entities: The TK-NOG Conditions of Use for for-profit users apply.

The CIEA NOG mouse® is produced and distributed under license rights to the following patents and trademarks:
Japanese Patent No. 3,753,321
US Patent No. 7,145,055; 5,464,764; 5,487,992; 5,627,059; 5,631,153; 5,789,215; 6,204,061; 6,653,113; 6,689,610
EU Patent No. 1,338,198
Japanese Trademark Reg. No. 4,823,423
US Trademark Reg. No. 3,118,040
EU Trademark Reg. No. 3,736,758